DLL3-Targeting Drug Now an Option for SCLC Free

The FDA granted accelerated approval to tarlatamab (Imdelltra; Amgen), a bispecific T-cell engager that targets delta-like ligand 3 (DLL3), to treat extensive-stage small cell lung cancer that has advanced despite receiving platinum-based chemotherapy. The decision was based on efficacy of the drug in 99 patients with the disease enrolled in the DeLLphi-301 trial, in which the overall response rate and duration of response were 40% and 9.7 months, respectively; reports of other research suggest that overall survival in these patients is rarely more than 8 months. Notably, tarlatamab carries a boxed warning for serious or life-threatening cytokine release syndrome and neurologic toxicity.